Phase IB study to evaluate the biological activity of indibulin using positron-emission tomography scans.

Trial Profile

Phase IB study to evaluate the biological activity of indibulin using positron-emission tomography scans.

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2013

At a glance

  • Drugs Indibulin (Primary)
  • Indications Solid tumours
  • Focus Therapeutic Use
  • Sponsors ZIOPHARM Oncology
  • Most Recent Events

    • 01 Jul 2009 Additional lead trial investigator identified as Jonathan Lewis as reported by ClinicalTrials.gov.
    • 01 Jul 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
    • 01 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top